Clinical and immunological aspects of hepatitis B virus infection in children receiving multidrug cancer chemotherapy

  • R. Repp
  • B. v. Hörsten
  • A. Csecke
  • J. Kreuder
  • A. Borkhardt
  • W. R. Willems
  • F. Lampert
  • W. H. Gerlich
Conference paper
Part of the Archives of Virology Supplementum book series (ARCHIVES SUPPL, volume 8)


For two reasons hepatitis B virus infection is an important problem in patients with cancer. First, multidrug cancer chemotherapy may reactivate or worsen a previously benign chronic HBV infection. Second, patients undergoing cancer chemotherapy are at an increased risk of acquiring and spreading HBV which may result in an endemic infection. HBV reactivation may precipitate into a severe acute disease including fulminant hepatitis. In contrast, the acquisition of HBV during cancer chemotherapy commonly takes a mild clinical course but frequently leads to persistently high viremia. This state of immunotolerance to viral antigens allows viral replication without any sign of liver cell destruction. Withdrawal of chemotherapy does not cause significant changes if infection occurred during cytotoxic chemotherapy. Infection with HBV during cancer chemotherapy, therefore, may be considered as a model of an induced antigen-specific immunotolerance. In agreement with this hypothesis, vaccination against HBV during cancer chemotherapy does not prevent spread of HBV in oncology wards as it does not produce significant anti-HBs titers. Furthermore, vaccination even suppresses the immune response to later booster doses after chemotherapy has been withdrawn.


Cancer Chemotherapy Hepatitis Delta Virus Pediatric Oncology Unit Patient Undergo Cancer Chemotherapy Liver Cell Destruction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baker JR Jr (1992) The immune response in chronic hepatitis B virus infection: the “core” of the problem. Hepatology 16: 498–500PubMedCrossRefGoogle Scholar
  2. 2.
    Beasley RP, Hwang LY, Lin CC, Chien CS (1981) Heaptocellular carcinomas and hepatitis B virus. A prospective study of 22, 707 men in Taiwan. Lancet ii: 1129–1133Google Scholar
  3. 3.
    Bertram U, Repp R, Fischer HP, Willems WR, Lampert F (1990) Hepatitis-B-Endemie bei zytostatisch behandelten Kindern. Dtsch Med Wochenschr 115: 1253–1254PubMedGoogle Scholar
  4. 4.
    Bird GLA, Smith H, Portmann B, Alexander GJM, Williams R (1989) Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med 73: 895–902PubMedGoogle Scholar
  5. 5.
    Blumberg BS, Alter HJ, Visnich S (1965) A “new” antigen in leukemia sera. JAMA 191: 101–106Google Scholar
  6. 6.
    Cote PJ, Korba BE, Baldwin B, Hornbuckle WE, Tennant BC, Gerin JL (1992) Immunosuppression with cyclosporine during the incubation period of experimental woodchuck hepatitis virus infection increases the frequency of chronic infection in adult woodchucks. J Infect Dis 166: 628–631PubMedCrossRefGoogle Scholar
  7. 7.
    Eddleston ALWF, Mondelli M (1986) Immunopathological mechanisms of liver injury in chronic hepatitis B virus infection. J Hepatol 3 [Suppl 2]: 17–23CrossRefGoogle Scholar
  8. 8.
    Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, Cavalli A, Petit M-A, Fiaccadori F (1990) Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145: 3442–3449PubMedGoogle Scholar
  9. 9.
    Flowers MA, Heathcote J, Wanless IR, Sherman M, Reynolds WJ, Cameron RG, Levy GA, Inman RD (1990) Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of lowdose methotrexate therapy. Ann Intern Med 112: 381–382PubMedGoogle Scholar
  10. 10.
    Franco E, Olivadese A, Valeri M, Albertoni F, Petrosillo N (1992) Control of hepatitis B virus infection in dialysis units in Latium, Italy. Nephron 61: 329–330PubMedCrossRefGoogle Scholar
  11. 11.
    Grunmayer ER, Panzer S, Ferenci P, Gander H (1989) Recurrence of hepatitis B in children with serological evidence of past B virus infection undergoing antileukemic chemotherapy. J Hepatol 8: 232–235CrossRefGoogle Scholar
  12. 12.
    Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96: 447–449PubMedGoogle Scholar
  13. 13.
    Hovi L, Saarinen UM, Jalanko H, Pohjanpelto P, Siimes MA (1991) Characteristics and outcome of acute infection with hepatitis B virus in children with cancer. Pediatr Infect Dis J 10: 809–812PubMedCrossRefGoogle Scholar
  14. 14.
    Karayiannis P, Goldin R, Luther S, Carman WF, Monjardino J, Thomas HC (1992) Effect of cyclosporin-A in woodchucks with chronic hepatitis delta virus infection. J Med Virol 36: 316–321PubMedCrossRefGoogle Scholar
  15. 15.
    Kumar A, Misra PK, Rana GS, Mehrotra R (1992) Infection with hepatitis A, B, Delta, and human immunodeficiency viruses in children receiving cycled cancer chemotherapy. J Med Virol 37: 83–86PubMedCrossRefGoogle Scholar
  16. 16.
    Lampert F, Willems WR, Bertram U, Berthold F (1987) No adverse prognostic influence of hepatitis B virus infection in acute childhood lymphoblastic leukemia. Blut 55: 115–120PubMedCrossRefGoogle Scholar
  17. 17.
    Lau JYN, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D (1989) Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 73: 911 - 917PubMedGoogle Scholar
  18. 18.
    Lien Y-HH, Schröter GPJ, Weil R III, Robinson WA (1991) Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporine-related lymphoma in a renal transplant recipient with acute pancreatitis. Transplantation 52: 739–742PubMedCrossRefGoogle Scholar
  19. 19.
    Locasciulli A, Alberti A, Rossetti F, Santamaria M, Santoro N, Madon E, Miniero R, Lo Curto M, Tamaro P, Paolucci P, Casale F, Nespoli L, Tucci F, Masera G (1985) Acute and chronic hepatitis in childhood leukemia: a multicentric study from the Italian Cooperative Group for Therapy of Acute Leukemia (AIL-AIEOP). Med Pediatr Oncol 13: 203–206PubMedCrossRefGoogle Scholar
  20. 20.
    Locasciulli A, Santamaria M, Masera G, Schiavon E, Alberti A, Realdi G (1985) Hepatitis B virus markers in children with acute leukemia: the effect of chemotherapy. J Med Virol 15: 29–33PubMedCrossRefGoogle Scholar
  21. 21.
    Lok ASF, Liang RHS, Chiu EKW, Wong K-L, Chan T-K, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182–188PubMedGoogle Scholar
  22. 22.
    Milich DR, Hughes JL, McLachlan A, Langley KE, Thornton GB, Jones JE (1990) Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. I. T cell fine specificity. J Immunol 144: 3535–3543PubMedGoogle Scholar
  23. 23.
    Milich DR, Jones JE, McLachlan A, Bitter G, Moriarty A, Hughes JL (1990) Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. II. Synthetic pre-S(2) immunogen. J Immunol 144: 3544–3551PubMedGoogle Scholar
  24. 24.
    Oguchi H, Miyasaka M, Tokunaga S, Hora K, Ichikawa S, Ochi T, Yamada K, Nagasawa M, Kanno Y, Aizawa T, Watanabe H, Yoshizawa S, Sato K, Terashima M, Yoshie T, Oguchi S, Tanaka E, Kiyosawa K, Furuta S (1992) Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 38: 36–43PubMedGoogle Scholar
  25. 25.
    Okamoto H, Tsuda F, Sakugawa H, Sastrosoewingnjo R, Imai M, Miyakawa Y, Mayumi M (1988) Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 69: 2575–2583PubMedCrossRefGoogle Scholar
  26. 26.
    Perrillo RP (1990) Factors influencing response to interferon in chronic hepatitis B: Implications for Asian and Western populations. Hepatology 12: 1433–1435PubMedCrossRefGoogle Scholar
  27. 27.
    Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S (1990) Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65: 878–884PubMedCrossRefGoogle Scholar
  28. 28.
    Ratner L, Peylan-Ramu N, Wesley R, Poplack DG (1986) Adverse prognostic influence of hepatitis B virus infection in acute lymphoblastic leukemia. Cancer 58: 1096–1100PubMedCrossRefGoogle Scholar
  29. 29.
    Repp R, Mance A, Bertram U, Niemann H, Gerlich WH, Lampert F (1991) Persistent hepatitis B virus replication in mononuclear blood cells as a source of reinfection of liver transplants. Transplantation 52: 935PubMedCrossRefGoogle Scholar
  30. 30.
    Repp R, von Hörsten B, Müller A, Bertram U, Kreuder J, Netz H, Lampert F (1991) Persistent immunotolerance to hepatitis B virus antigens after infection during polychemotherapeutic treatment for malignancies. In: Touraine JL, Traeger J, Bétuel H, Dubernard JM, Revillard JP, Dupuy C (eds) Transplantation and clinical immunology vol 23: virus and transplantation. Excerpta Medica, Amsterdam, p 384Google Scholar
  31. 31.
    Rostoker G, Rosenbaum J, Ben Maadi A, Nedelec G, Deforge L, Vidaud M, Lang P, Lagrue G, Goossens M, Weil B (1990) Reactivation of hepatitis B virus by corticosteroids in a case of idiopathic nephrotic syndrome. Nephron 56: 224PubMedCrossRefGoogle Scholar
  32. 32.
    Steinberg SC, Alter HJ, Leventhal BG (1975) The risk of hepatitis transmission to family contacts of leukemic patients. J Pediatr 87: 753–756PubMedCrossRefGoogle Scholar
  33. 33.
    Stitz L, Soeder D, Deschl U, Frese K, Rott R (1989) Inhibition of immunemediated meningoencephalitis in persistently borna disease virus-infected rats by cyclosporine A. J Immunol 143: 4250–4256PubMedGoogle Scholar
  34. 34.
    Tabor E, Gerety RJ, Mott M, Welburg J (1978) Prevalence of hepatitis B in high risk setting. A serologic study of patients and staff in a pediatric oncology unit. Pediatrics 61: 711–715PubMedGoogle Scholar
  35. 35.
    Thomas HC (1989) Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers: implications for the treatment of chronic HBV carriers. Q J Med 73: 873–874PubMedGoogle Scholar
  36. 36.
    Thomas HG (1990) The hepatitis B virus and the host response. J Hepatol 11 [Suppl 1]: S83–S89PubMedCrossRefGoogle Scholar
  37. 37.
    Thomas HC (1990) Hepatitis B virus-induced liver disease. Springer Semin Immunopathol 12: 1–3CrossRefGoogle Scholar
  38. 38.
    Vandercam B, Cornu C, Gala JL, Geubel A, Cahill M, Lamy ME (1990) Reactivation of hepatitis B virus in a previously immune patient with human immunodeficiency virus infection. Eur J Clin Microbiol Infect Dis 9: 701–702PubMedCrossRefGoogle Scholar
  39. 39.
    Wagner D, Wagenbreth I, Stachan-Kunstyr R, Flik J (1992) Failure of vaccination against hepatitis B with Gen H-B- Vax-D in immunosuppressed heart transplant recipients. Klin Wochenschr 70: 585–587Google Scholar
  40. 40.
    Wands JR, Chura CM, Roll FJ, Maddrey WC (1975) Serial studies of hepatitis associated antigen and antibody in patients recieving anti tumor chemotherapy for myeloproliverative and lymphoproliverative disorders. Gastroenterology 68: 105–111PubMedGoogle Scholar
  41. 41.
    Wen Y-M, Xu Y-Y (1991) Pathogenesis and immune responses in hepatitis B patients and carriers. Monogr Virol 19: 31–39Google Scholar
  42. 42.
    Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S (1992) Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 37: 1253–1259PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • R. Repp
    • 1
  • B. v. Hörsten
    • 1
  • A. Csecke
    • 1
  • J. Kreuder
    • 1
  • A. Borkhardt
    • 1
  • W. R. Willems
    • 2
  • F. Lampert
    • 1
  • W. H. Gerlich
    • 2
  1. 1.Department of PediatricsJustus-Liebig-UniversityGiessenFederal Republic of Germany
  2. 2.Department of Medical VirologyJustus-Liebig-UniversityGiessenFederal Republic of Germany

Personalised recommendations